Items tagged with Drug-resistant TB
Following US FDA approval, child-friendly bedaquiline available from Stop TB Partnership's GDF Pediatric DR-TB Initiative (post)
11 June 2020, Geneva, Switzerland– The Stop TB Partnership’s Global Drug Facility (GDF) today announced the addition of child-friendly bedaquiline 20 mg tablets to the GDF Pediatric DR-TB Initiative. The US FDA approval of the medicine, on 27 May 2020, marks a new milestone for all-oral DR-TB regimens in children who are older than 5 years of age and weighing more than 15 kilograms. These children will now benefit from the same optimized treatments being provided to their parents – no more injections for anyone.
High price excludes patients from better treatment for drug-resistant TB (post)
NAIROBI — Sheila Baraza, a 30-year-old resident of Ruaka, a city to the northwest of Nairobi, unsuccessfully fought back tears as she recalled the pain of seeking and then undertaking a two-year treatment for drug-resistant tuberculosis.
Rigid treatments can cause disease to spread (post)
Rigid treatments of tuberculosis could lead to the emergence of more drug-resistant tuberculosis instead of less, new study shows.
RESIST-TB newsletter (post)
RESIST-TB released its June 2020 newsletter with the latest research publications on drug-resistant TB.
Webinar: From Policy to Practice: Rolling out new WHO guidelines on rapid diagnostics and drug-resistant TB treatment (post)
The World Health Organization (WHO) will host a webinar on 9 July 2020 to provide key updates on recently released new WHO guidance on rapid diagnostics and drug-resistant TB treatment.
Mylan secures DCGI approval in India for pretomanid, a treatment for highly drug-resistant forms of TB (post)
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years
Approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance
RESIST-TB July 2020 newsletter (post)
RESIST-TB released its July 2020 newsletter with the latest research publications on drug-resistant TB.
TB Alliance announces European Commission authorisation of new treatment for highly drug-resistant TB (post)
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
Penn Medicine-led research suggests greater access to specific HIV and TB medications is needed worldwide (post)
A specific combination of HIV and TB treatments, difficult to obtain in certain parts of the world, decreased mortality risk for patients with HIV and multidrug-resistant TB.
RESIST-TB newsletter (post)
RESIST-TB released its August 2020 newsletter with the latest research publications on drug-resistant TB.
Page 65 of 117 · Total posts: 0
←First 64 65 66 Last→